Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule

May 18, 2026 10:44 AM EDT R&D Mer­ck­'s ADC sac-TMT gets its first glob­al Phase 3 win ahead of sched­ule Max Gelman Senior Editor An ex­per­i­men­tal an­ti­body-drug con­ju­gate from Mer­ck and Chi­na-based Kelun-Biotech suc­ceed­ed in a glob­al Phase 3 study for the first time, giv­ing Mer­ck a key pipeline … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER